Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

3 Dec 2020

Abstract excerpt

Acute myeloid leukemia (AML) remains a devastating disease in need of new therapies to improve patient survival. Targeted adoptive T-cell therapies have achieved impressive clinical outcomes in some B-cell leukemias and lymphomas but not in AML. Double-negative T cells (DNTs) effectively kill blast cells from the majority of AML patients and are now being tested in clinical trials. However, AML blasts obtained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Cytomegalovirus and herpesvirus research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33270841
DOI: 10.1182/blood.2019004108

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapyPMID 33270841Read ↗

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML TherapySemantic proximity Read ↗

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemiaSemantic proximity Read ↗

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia.Semantic proximity Read ↗

Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screeningSemantic proximity Read ↗

Identification of novel genetic vulnerabilities and therapeutic targets in acute myeloid leukaemia using CRISPR dropout screensSemantic proximity Read ↗

High-Throughput CRISPR Screening in Hematological NeoplasmsSemantic proximity Read ↗

Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implicationsSemantic proximity Read ↗

Applying CRISPR-based genetic screens to identify drivers of tumor-cell sensitivity towards NK-cell attackSemantic proximity Read ↗

Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 screen identifies AraC-daunorubicin-etoposide response modulators associated with outcomes in pediatric AMLSemantic proximity Read ↗

Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.